Skip to content
BALCAO · MEDICINAL CHEMICALS & BOTANICAL PRODUCTS · LARGE CAP

Curaleaf Holdings, Inc. CURLF

5 fiscal years on record · USD · FY2025 reported · SEC filings only
$1.3B
▼ 5.0% YoY
$-231.1M
$74.3M
▲ 4.3% YoY

Slide the table for earlier years · "·" marks a figure not available in our data for that year.

In brief

What this company does

Curaleaf Holdings, Inc. operates a vertically integrated cannabis platform with an omnichannel distribution footprint and a portfolio of brands and products serving consumers and patients across the U.S., Canada, Europe and Australasia. Its product portfolio includes flower, pre-rolls, vaporizer cartridges, concentrates, topicals, tinctures, edibles and beverages. As at December 31, 2025, the company had 5,554 employees, of which 4,862 were located in the U.S., 92 in Canada, 598 in Europe and 2 in Australia. Its infrastructure includes 17 cultivation sites with approximately 1,489,814 square feet of cultivation capacity. As of December 31, 2025, the company had two operating segments: Domestic operations and International operations. In the United States, the company sells cannabis primarily through direct-to-consumer retail sales at state-licensed dispensaries. In Europe, its sales occur primarily through licensed wholesale distribution channels in Germany, Poland, Switzerland and the United Kingdom.

Written from the business description in Curaleaf Holdings, Inc.'s annual report to the U.S. Securities and Exchange Commission, filed 27 February 2026. Every sentence was checked against that document before publication.

Growth

USD 1.3B
Revenue, FY2025 · full 5-year series below
Revenue $B Net income $B
FY2025 · Revenue 1.3 · Net income -0.2
0.5B1.0B-0.1B-0.3B
202120242025
Compound annual growth
−0.2%
3 yrs
5 yrs
10 yrs
15 yrs

Compound annual rates per period — left blank where that exact year isn't on file, the series crosses a loss, or (per-share rows) a split falls inside the window.

Profitability

−18 cents
lost on every revenue dollar
Operating margin Net margin
FY2025 · Operating 2.0% · Net -18.0%
2%4%-10%-20%
202120232025
ROE
FY2025 · ROE -28.6%
-10%-20%
202120232025
Three returns, three denominators.

Each USD of equity lost 29 cents this year.

Cash & shareholders

·
returned in FY2025 · dividends + net buybacks
Free cash flow $M
FY2025 · FCF 74.3
30M60M-100M-200M
202120232025

Total assetsUSD 2.8B
EquityUSD 756.4M
CashUSD 101.6M
Gross debtUSD 548.7M
Net debtUSD 447.1M
Current ratio1.52×

Net debt stands at 59% of equity.

The 5-year record

5 fiscal years
Every figure from documents filed with the SEC · USD
row low → row highnegative—not applicable◌not available in our data
CURLF, 5-year financial record
Metric 20252024202320222021
Revenue $B1.31.31.31.31.2
Operating income $B0.00.00.00.10.1
EBITDA $B0.20.30.20.20.2
Income tax $B0.10.10.10.20.2
Net income $B−0.2−0.2−0.3−0.4−0.2
Free cash flow $B0.10.10.0−0.1−0.2
EPS, diluted $−0.35−0.32−0.39−0.52−0.29
Dividend / sh $◌◌◌◌◌
Payout % — not applicable: no dividend—————
ROE %−28.6−22.5−24.1−26.2−13.3
Shares out B◌0.750.730.720.71

Slide the table for earlier years. "—" not applicable · "◌" not available in our data.

Compare

This company against its peers

More in this sector

Other companies filing in the same sector

Provenance

Company facts, as filed

How we verify · 0 failures · 2 divergences in 25 reconciliationsAUDITED

Reconciled in 3 of the 5 fiscal years we could check. 2 of those reconciliations are divergences — the figures exist but don't fit the formula this check expects; that isn't the same as an error. 28 checks were skipped: the balance sheet is not tagged before 2021. 14 checks were skipped: EPS is not tagged before 2021. 14 checks were skipped: revenue is not tagged before 2021.

EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidityCurrency consistency0 failures2 divergent
ActivityMedicinal Chemicals & Botanical Products
Listed onOTC market
Incorporated inoutside the United States — SEC code A1
Fiscal year endsDecember 31
Data on record since2021

Share this section

Download image